Proximal Humeral Fracture
Conditions
Brief summary
The study at hand aimed to analyze the replicability of the observed treatment effects in these studies published by Koeppe et al. and Stolberg-Stolberg et al.
Detailed description
see Protocol
Interventions
PROCEDURERTSA
Sponsors
Universität Münster
University Hospital Muenster
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- all patients will be included, who had an inpatient coded treatment using LPF or RTSA
Exclusion criteria
* Incomplete insurance status within two years before index * Incomplete basic information * Age\<65 years * Missing diagnosis of PHF (ICD: S42.2) within two years before surgery * Previous surgical treatment (RTSA, LPF or other fracture fixation) * Coded polytrauma * Bone tumors/ bone metastasis * Both sides or missing information of surgery side * COVID-19 infection during index hospitalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Surgical complications after discharge | up to 12 years | Time from discharge of index hospitalization to surgical complications, with death being considered as a competing risk event. |
| Thromboembolic events during index | through hospital stay, an average of 16 days | See above, only events during hospitalization |
| Thromboembolic events (or death) after discharge | up to 12 years | Time from discharge of index hospitalization to a thromboembolic event or death of any case. |
| Surgical complications during index case | through hospital stay, an average of 16 days | See above, only events during hospitalization |
| 30-day mortality | 30 days | Death from any cause during the first 30-days after surgery. |
| Overall survival (OS) | up to 12 years | Time from discharge of index hospitalization to death of any case. |
| Major adverse events during index case | through hospital stay, an average of 16 days | See above, only events during hospitalization |
| Major adverse events after discharge | up to 12 years | Time from discharge of index hospitalization to MAE as defined above |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Non-Implant-associated complication during index | through hospital stay, an average of 16 days | See above, only events during hospitalization |
| Minor outpatient complications after discharge | up to 12 years | Time from discharge of index hospitalization to minor outpatient complications, with death being considered as a competing risk event. |
| Implant-associated complication during index | through hospital stay, an average of 16 days | See above, only events during hospitalization |
Outcome results
None listed